Publications by authors named "Todd Zimmerman"

Claim this Profile
A
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.
Steven P Treon, Camille N Kotton, David J Park, Giorgia Moranzoni, Camilla K Lemvigh, Todd Zimmerman

Front Immunol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A standardized educational program to improve peripheral vascular access outcomes in the emergency department: A quasi-experimental pre-post trial.
Amit Bahl, Nicholas Mielke, Yuying Xing, Emily DiLoreto, Todd Zimmerman

J Vasc Access· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kevin R Kelly, Sikander Ailawadhi, David S Siegel, Leonard T Heffner, George Somlo, Todd M Zimmerman

Lancet Haematol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Saad Z Usmani, Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Todd Zimmerman

Lancet Haematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Jagoda K Jasielec, Tadeusz Kubicki, Noopur Raje, Ravi Vij, Donna Reece, Todd M Zimmerman

Blood· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
Benjamin A Derman, Yuanyuan Zha, Todd M Zimmerman, Rebecca Malloy, Andrzej Jakubowiak

J Immunother Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Andrzej J Jakubowiak, Jagoda K Jasielec, Cara A Rosenbaum, Craig E Cole, Ajai Chari, Todd M Zimmerman

Br J Haematol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
Sundar Jagannath, Leonard T Heffner, Sikander Ailawadhi, Nikhil C Munshi, Todd M Zimmerman

Clin Lymphoma Myeloma Leuk· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
Jonathan L Kaufman, Roberto Mina, Andrzej J Jakubowiak, Todd L Zimmerman, Jeffrey J Wolf

Blood Cancer J· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of functional folate receptors in multiple myeloma.
Ying Zhou, Kenji Unno, Elizabeth Hyjek, Hui Liu, Todd Zimmerman

Leuk Lymphoma· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tibiofemoral Contact Mechanics With Horizontal Cleavage Tears and Treatment of the Lateral Meniscus in the Human Knee: An In Vitro Cadaver Study.
Jason L Koh, Todd A Zimmerman, Savan Patel, Yupeng Ren, Dali Xu

Clin Orthop Relat Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arthroscopic treatment successfully treats posterior elbow impingement in an athletic population.
Jason L Koh, Brad A Zwahlen, David W Altchek, Todd A Zimmerman

Knee Surg Sports Traumatol Arthrosc· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Andrew Spencer, Simon Harrison, Jeffrey Zonder, Ashraf Badros, Jacob Laubach, Todd Zimmerman

Br J Haematol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.
Erik H van Beers, Martin H van Vliet, Rowan Kuiper, Leonie de Best, Kenneth C Anderson, Todd M Zimmerman

Clin Lymphoma Myeloma Leuk· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.
Kristin A Rand, Chi Song, Eric Dean, Daniel J Serie, Karen Curtin, Todd Zimmerman

Cancer Epidemiol Biomarkers Prev· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tibiofemoral Contact Mechanics with Horizontal Cleavage Tear and Resection of the Medial Meniscus in the Human Knee.
Jason L Koh, Seung Jin Yi, Yupeng Ren, Todd A Zimmerman, Li-Qun Zhang

J Bone Joint Surg Am· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Paul G Richardson, Todd M Zimmerman, Craig C Hofmeister, Moshe Talpaz, Asher A Chanan-Khan

Blood· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
Shaji K Kumar, Amrita Krishnan, Betsy LaPlant, Kristina Laumann, Vivek Roy, Todd Zimmerman

Am J Hematol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitochondria DNA mutations cause sex-dependent development of hypertension and alterations in cardiovascular function.
Mark J Golob, Lian Tian, Zhijie Wang, Todd A Zimmerman, Christine A Caneba

J Biomech· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Shaji K Kumar, William I Bensinger, Todd M Zimmerman, Craig B Reeder, James R Berenson

Blood· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.
Sheeba K Thomas, Alexander Suvorov, Lucien Noens, Oleg Rukavitsin, Joseph Fay, Todd M Zimmerman

Cancer Chemother Pharmacol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Andrzej J Jakubowiak, Paul G Richardson, Todd Zimmerman, Melissa Alsina, Jonathan L Kaufman

Br J Haematol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
Andrzej J Jakubowiak, Don M Benson, William Bensinger, David S D Siegel, Todd M Zimmerman

J Clin Oncol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.
George Somlo, Ashkan Lashkari, William Bellamy, Todd M Zimmerman, Joseph M Tuscano

Br J Haematol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Andrzej J Jakubowiak, Kent A Griffith, Donna E Reece, Craig C Hofmeister, Sagar Lonial, Todd M Zimmerman

Blood· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis